Celltrion Group’s honorary chairman Seo Jeong-jin held an online press conference on the 18th to announce the treatment of Corona 19, such as Rekkironaju. Celltrion YouTube screen capture
Celltrion Honorary Chairman Seo Jeong-jin showed the possibility of jumping into the development of a Corona 19 vaccine to secure technological sovereignty. During the development of the COVID-19 treatment’Rekironaju’, they showed confidence that they could respond to mutant viruses by securing candidate antibodies.
Chairman Seo held an online press conference on the morning of the 18th, saying, “If you can make antibodies, you can already make antigens.” I have no choice but to worry.”
Celltrion is said to have secured the technology to create antigens during the development of the antibody treatment, Rekirona. Vaccine is a method that induces an immune response by injecting a viral antigen into the human body, so it is explained that it is possible to develop a vaccine using existing technologies.
However, if domestic companies such as SK Bioscience are delayed in development of domestic vaccines or the status of overseas vaccine acquisitions are monitored, the development will be considered if supply is insufficient. Chairman Seo said, “It is not a business with economic feasibility, and we have not decided immediately,” he said. “If it is necessary for national technology independence, we are ready to develop it urgently without considering profitability.”
“Available to respond to mutant viruses… Equipped with an antibody platform”
Celltrion’s corona mutation response platform. Celltrion provided
Regarding the point that Rekirona has little effect on mutations originating in South Africa, he expressed confidence that he would develop a’customized treatment’ using a new candidate antibody that he had secured.
Chairman Seo said, “Even if a new mutation occurs, we have a neutralizing antibody platform that can find an appropriate antibody and develop it as a therapeutic agent in a short period of time.” I will.”
Celltrion has secured 38 neutralizing antibodies capable of responding to mutant viruses from the early stages of Rekirona development. Of these, candidate antibody No. 32 showed neutralizing ability to neutralize both the British and South African mutant viruses, and it is explained that a new mutant treatment will be developed based on this antibody. The clinical trial is scheduled to be conducted alone in South Africa after an animal test next month.
Meanwhile, Rekkironaju, which started supplying to medical institutions from the previous day, will produce an additional 400,000 people by next month in addition to the 100,000 people it produced. The annual maximum output is 3.2 million people. Celltrion plans to flexibly produce 1.5 to 3.2 million people according to demand.
Sora Lee reporter [email protected]
News directly edited by the Hankook Ilbo can also be viewed on Naver.
